RULES: Implantation or Injectable Dosage Form New Animal Drugs; Flunixin,
Published: 2008-05-15
The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of a supplemental abbreviated new
animal drug application (ANADA) filed by IVX Animal Health, Inc. The [[Page 28037]]
supplemental ANADA provides for the veterinary prescription use of
flunixin meglumine solution by intravenous injection in lactating
NOTICES: Biophysics of Neural Systems Study Section; change,
Published: 2008-05-15
Notice is hereby given of a change in the meeting of the Biophysics
of Neural Systems Study Section, June 12, 2008, 8 a.m. to June 12,
2008, 8 p.m., Hotel Lombardy, 2019 Pennsylvania Avenue, NW.,
Washington, DC 20006 which was published in the Federal Register on April 29, 2008, 73 FR 2325723259.
The meeting will be held June 12, 2008, 8
NOTICES: Determination of Regulatory Review Period for Purposes of Patent Extension; TYZEKA,
Published: 2008-05-15
The Food and Drug Administration (FDA) has determined the
regulatory review period for TYZEKA and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submissions of applications to the Director of Patents
and Trademarks, Department of Commerce, for the extension of patents
which claim
NOTICES: Center for Scientific Review Special Emphasis Panel; Cancellation,
Published: 2008-05-15
Notice is hereby given of the cancellation of the Center for
Scientific Review Special Emphasis Panel, June 10, 2008, 6 a.m. to June
11, 2008, 6 p.m., National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 which was published in the Federal Register on April 29, 2008, 73 FR 2325723259.
The meeting is cancelled due to the
NOTICES: Immunology Integrated Review Group,
Published: 2008-05-15
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the
NOTICES: Agency Information Collection Activities; Proposals, Submissions, and Approvals,
Published: 2008-05-15
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these
documents, call the SAMHSA Reports Clearance Officer on (240) 2761243.
Project: Opioid
NOTICES: Musculoskeletal, Oral and Skin Sciences Integrated Review Group and Others,
Published: 2008-05-15
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the
NOTICES: National Institute on Aging Initial Review Group Biological Aging Review Committee,
Published: 2008-05-15
Pursuant to section 10(d) of the Federal Advisory Committee Act, as [[Page 28124]]
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and
NOTICES: National Institute on Aging Special Emphasis Panel,
Published: 2008-05-15
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the
NOTICES: Statement of Organization, Functions, and Delegations of Authority,
Published: 2008-05-15
The Statement of Organization, Functions, and Delegations of
Authority Part N, National Institutes of Health (NIH), of the Statement
of Organization, Functions, and Delegations of Authority for the
Department of Health and Human Services (DHHS) (40 FR 22859, May 27,
1975, as amended most recently at 71 FR 46495, August 14, 2006, and
NOTICES: National Institute of Environmental Health Sciences,
Published: 2008-05-14
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions
NOTICES: National Institute of General Medical Sciences Special Emphasis Panel,
Published: 2008-05-14
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions
RULES: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements; Technical Amendment,
Published: 2008-05-14
The Food and Drug Administration (FDA) is correcting a final
rule that appeared in the Federal Register of June 25, 2007 (72 FR
34752). The final rule established current good manufacturing practice
(CGMP) requirements in manufacturing, packaging, labeling, or holding
operations for dietary supplements. The final rule was published with
an
NOTICES: AVASTIN,
Published: 2008-05-14
The Food and Drug Administration (FDA) has determined the
regulatory review period for AVASTIN and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Director of Patents
and Trademarks, Department of Commerce, for the extension of a patent
which
NOTICES: INVEGA,
Published: 2008-05-14
The Food and Drug Administration (FDA) has determined the
regulatory review period for INVEGA and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Director of Patents
and Trademarks, Department of Commerce, for the extension of a patent
which
NOTICES: Agency Information Collection Activities; Proposals, Submissions, and Approvals,
Published: 2008-05-14
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
NOTICES: ZOLINZA,
Published: 2008-05-14
The Food and Drug Administration (FDA) has determined the
regulatory review period for ZOLINZA and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Director of Patents
and Trademarks, Department of Commerce, for the extension of a patent
which
NOTICES: Agency Information Collection Activities; Proposals, Submissions, and Approvals,
Published: 2008-05-14
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 6395960 or send an email
NOTICES: National Center for Injury Prevention and Control Initial Review Group,
Published: 2008-05-14
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned review group:
Name: National Center for Injury Prevention and Control Initial Review Group (NCIPC/IRG).
Time and Date: 1 p.m.3 p.m., May 16,
NOTICES: Fogarty International Center Advisory Board,
Published: 2008-05-14
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Fogarty International Center Advisory Board.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special